Nipah virus envelope pseudotyped lentiviruses and methods of their use
AssigneeThe Regents of the University of California
InventorsBenhur LEE, Karina PALOMARES, Olivier PERNET
Life of this patent
Estimating the term…
Abstract
The present invention realtes to lentiviral particles which have been pseudotyped with Nipah virus (NiV) fusion (F) and attachment (G) glycoproteins (NiVpp-F/G). Additionally, the present invention relates to truncated NiV-F glyocproteins useful in producing such NiVpp lentiviral particles, as well as to additional variant peptides which enhance activity. Further, the present invention relates to methods of using such lentiviral particles or sequences, for example in the treatetment of cancer or CNS disorders.
Claims36
1-11. (canceled)
A method of delivering a nucleic acid to a cell, the method comprising contacting a Nipah virus (NiV) envelope pseudotyped lentivirus particle comprising a nucleic acid for delivery with cells,
- wherein the NiV pseudotyped lentivirus particle comprises Nipah Virus fusion (NiV-F) and Nipah Virus attachment (NiV-G) proteins,
- wherein the NiV-F protein comprises a deletion in its cytoplasmic tail relative to a wild type NiV-F sequence, wherein the NiV-F protein comprises a cytoplasmic tail lacking amino residues 525-546 of SEQ ID NO:
- 1,
- wherein the NiV-G protein is wild-type NiV-G or is a NiV-G protein that has a cytoplasmic tail truncation comprising a deletion in its cytoplasmic tail relative to wild type NiV-G sequence,
- and wherein the NiV envelope pseudotyped lentivirus particle has increased viral transduction titer compared to a lentivirus particle pseudotyped with wild-type NiV-F and wild-type NiV-G.
A method of delivering a nucleic acid to a cell, the method comprising administering a therapeutically effective amount of a NiV pseudotyped lentivirus particle comprising a nucleic acid for delivery to a subject,
- wherein the NiV pseudotyped lentivirus particle comprises Nipah Virus fusion (NiV-F) and Nipah Virus attachment (NiV-G) proteins,
- wherein the NiV-F protein comprises a deletion in its cytoplasmic tail relative to a wild type NiV-F sequence, wherein the NiV-F protein comprises a cytoplasmic tail lacking amino residues 525-546 of SEQ ID NO:
- 1,
- wherein the NiV-G protein is wild-type NiV-G or is a NiV-G protein that has a cytoplasmic tail truncation comprising a deletion in its cytoplasmic tail relative to wild type NiV-G sequence,
- and wherein the NiV envelope pseudotyped lentivirus particle has increased viral transduction titer compared to a lentivirus particle pseudotyped with wild-type NiV-F and wild-type NiV-G.
A pharmaceutical composition comprising a Nipah virus (NiV) envelope pseudotyped lentivirus particle, wherein the NiV pseudotyped lentivirus particle comprises Nipah Virus fusion (NiV-F) and Nipah Virus attachment (NiV-G) proteins,
- wherein the NiV-F protein comprises a deletion in its cytoplasmic tail relative to a wild type NiV-F sequence, wherein the NiV-F protein comprises a cytoplasmic tail lacking amino residues 525-546 of SEQ ID NO:
- 1,
- wherein the NiV-G protein is wild-type NiV-G or is a NiV-G protein that has a cytoplasmic tail truncation comprising a deletion in its cytoplasmic tail relative to wild type NiV-G sequence,
- and wherein the NiV envelope pseudotyped lentivirus particle has increased viral transduction titer compared to a lentivirus particle pseudotyped with wild-type NiV-F and wild-type NiV-G.
A method of producing a Nipah virus (NiV) envelope pseudotyped lentivirus particle, the method comprising culturing producer cells comprising one or more nucleic acids for the production of the lentiviral particle under conditions for producing the lentiviral particle by the host cells,
- wherein the NiV pseudotyped lentivirus particle comprises Nipah Virus fusion (NiV-F) and Nipah Virus attachment (NiV-G) proteins,
- wherein the NiV-F protein comprises a deletion in its cytoplasmic tail relative to a wild type NiV-F sequence, wherein the NiV-F protein comprises a cytoplasmic tail lacking amino residues 525-546 of SEQ ID NO:
- 1,
- wherein the NiV-G protein is wild-type NiV-G or is a NiV-G protein that has a cytoplasmic tail truncation comprising a deletion in its cytoplasmic tail relative to wild type NiV-G sequence,
- and wherein the NiV envelope pseudotyped lentivirus particle has increased viral transduction titer compared to a lentivirus particle pseudotyped with wild-type NiV-F and wild-type NiV-G.
Dependencies are inferred from the claim text.